SK7832001A3 - Diazepinoindoles for treating chronic obstruction bronchopulmonary disease - Google Patents

Diazepinoindoles for treating chronic obstruction bronchopulmonary disease Download PDF

Info

Publication number: SK7832001A3
Authority: SK; Slovakia
Prior art keywords: amino; diazepino; tetrahydro; oxo; phenyl
Prior art date: 2000-06-09

Application number

SK783-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Annette Doherty

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-09

Filing date

2001-06-07

Publication date

2002-05-09

2001-06-07 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2002-05-09 Publication of SK7832001A3 publication Critical patent/SK7832001A3/sk

Links

BSYFXFLGOGQHFU-UHFFFAOYSA-N pyrrolo[2,3-g][1,2]benzodiazepine Chemical class N1=NC=CC=C2C3=NC=CC3=CC=C21 BSYFXFLGOGQHFU-UHFFFAOYSA-N 0.000 title claims abstract description 16
230000001684 chronic effect Effects 0.000 title description 5
208000027775 Bronchopulmonary disease Diseases 0.000 title description 2
206010061876 Obstruction Diseases 0.000 title 1
238000011282 treatment Methods 0.000 claims abstract description 25
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 11
125000003118 aryl group Chemical group 0.000 claims abstract description 7
125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
229910052757 nitrogen Inorganic materials 0.000 claims description 14
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 9
-1 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro- [1,4] diazepino [6,7,1-hi] indol-3-yl Chemical group 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 6
125000003545 alkoxy group Chemical group 0.000 claims description 5
KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 5
125000000623 heterocyclic group Chemical group 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 4
125000005842 heteroatom Chemical group 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Chemical group 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
229910052717 sulfur Inorganic materials 0.000 claims description 4
239000011593 sulfur Chemical group 0.000 claims description 4
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
150000001408 amides Chemical class 0.000 claims description 3
125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
125000001188 haloalkyl group Chemical group 0.000 claims description 3
UKQWQVZAPWMWED-UHFFFAOYSA-N 11-amino-9-phenyl-6-pyrrolidin-1-yl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound C1=2C3=CC(N4CCCC4)=CC=2CCN1C(=O)C(N)N=C3C1=CC=CC=C1 UKQWQVZAPWMWED-UHFFFAOYSA-N 0.000 claims description 2
HPXAUSKCFMFNEW-UHFFFAOYSA-N 6,11-diamino-9-phenyl-1,10-diazatricyclo[6.4.1.04,13]trideca-4(13),5,7,9-tetraen-12-one Chemical compound C1=2C3=CC(N)=CC=2CCN1C(=O)C(N)N=C3C1=CC=CC=C1 HPXAUSKCFMFNEW-UHFFFAOYSA-N 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
QVPUISMYRDHJMF-UHFFFAOYSA-N O=C1C=C2N=NC=CC=C2C2=C1C=CN2 Chemical group O=C1C=C2N=NC=CC=C2C2=C1C=CN2 QVPUISMYRDHJMF-UHFFFAOYSA-N 0.000 claims description 2
150000001721 carbon Chemical group 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000002950 monocyclic group Chemical group 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
XGXOSJSGDNPEEF-NRFANRHFSA-N dsstox_cid_27291 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)N)C=1C=CC=CC=1)C(=O)C1=CC=CN=C1 XGXOSJSGDNPEEF-NRFANRHFSA-N 0.000 claims 1
VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
150000001875 compounds Chemical class 0.000 description 30
239000002158 endotoxin Substances 0.000 description 24
229920006008 lipopolysaccharide Polymers 0.000 description 24
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 description 19
229950001653 cilomilast Drugs 0.000 description 17
229940125904 compound 1 Drugs 0.000 description 16
239000000203 mixture Substances 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 12
239000003826 tablet Substances 0.000 description 10
241000699670 Mus sp. Species 0.000 description 9
210000004027 cell Anatomy 0.000 description 9
210000000440 neutrophil Anatomy 0.000 description 9
235000002639 sodium chloride Nutrition 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
239000000443 aerosol Substances 0.000 description 8
239000000843 powder Substances 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
239000000243 solution Substances 0.000 description 7
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
239000002775 capsule Substances 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000000694 effects Effects 0.000 description 6
206010029379 Neutrophilia Diseases 0.000 description 5
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 5
201000010099 disease Diseases 0.000 description 5
239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 5
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 4
241000700157 Rattus norvegicus Species 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000007937 lozenge Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229950005741 rolipram Drugs 0.000 description 4
238000012360 testing method Methods 0.000 description 4
206010006458 Bronchitis chronic Diseases 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
YPZARNMVEFFLNZ-UHFFFAOYSA-N 1,10-diazatricyclo[6.4.1.04,13]trideca-2,4(13),5,7,9,11-hexaene Chemical class C1=CN=CC2=CC=CC3=C2N1C=C3 YPZARNMVEFFLNZ-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229920005372 Plexiglas® Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
208000007451 chronic bronchitis Diseases 0.000 description 2
229940110456 cocoa butter Drugs 0.000 description 2
235000019868 cocoa butter Nutrition 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012669 liquid formulation Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000000414 obstructive effect Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
QIMCTRHEMFULEC-UHFFFAOYSA-N 4,7-dimethylpyrazolo[5,1-c][1,2,4]triazine Chemical compound N1=NC=C(C)N2N=C(C)C=C21 QIMCTRHEMFULEC-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010009126 Chronic respiratory failure Diseases 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
238000002738 Giemsa staining Methods 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
CFBUZOUXXHZCFB-LDTOLXSISA-N cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylic acid Chemical compound COC1=CC=C([C@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-LDTOLXSISA-N 0.000 description 1
239000003086 colorant Substances 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000009509 drug development Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000007689 inspection Methods 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000004199 lung function Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
RMCDUNHIVVEEDD-UHFFFAOYSA-N methylcyclopropane Chemical compound [CH2]C1CC1 RMCDUNHIVVEEDD-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000012768 molten material Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
235000012771 pancakes Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
125000004385 trihaloalkyl group Chemical group 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000011345 viscous material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SK783-2001A 2000-06-09 2001-06-07 Diazepinoindoles for treating chronic obstruction bronchopulmonary disease SK7832001A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP00401646A EP1161949A1 (en)	2000-06-09	2000-06-09	Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease

Publications (1)

Publication Number	Publication Date
SK7832001A3 true SK7832001A3 (en)	2002-05-09

Family

ID=8173724

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK783-2001A SK7832001A3 (en)	2000-06-09	2001-06-07	Diazepinoindoles for treating chronic obstruction bronchopulmonary disease

Country Status (19)

Country	Link
US (1)	US6544983B2 (cs)
EP (1)	EP1161949A1 (cs)
JP (1)	JP2002138090A (cs)
KR (1)	KR20010111457A (cs)
CN (1)	CN1345725A (cs)
AR (1)	AR030291A1 (cs)
AU (1)	AU5181301A (cs)
BR (1)	BR0102289A (cs)
CA (1)	CA2347337A1 (cs)
CZ (1)	CZ20011999A3 (cs)
EA (1)	EA200100515A3 (cs)
HU (1)	HUP0102388A3 (cs)
IL (1)	IL143636A0 (cs)
MX (1)	MXPA01005726A (cs)
NO (1)	NO20012831L (cs)
NZ (1)	NZ512222A (cs)
PL (1)	PL347922A1 (cs)
SK (1)	SK7832001A3 (cs)
ZA (1)	ZA200104616B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050026883A1 (en) *	2003-07-31	2005-02-03	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) *	2003-07-31	2005-04-21	Robinson Cynthia B.	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) *	2003-07-31	2009-11-05	Robinson Cynthia B	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
PT1685849E (pt) *	2003-11-20	2012-02-15	Astellas Pharma Inc	Inibidores de pde4 para o tratamento da cistite intersticial
DE102004002557A1 (de) *	2004-01-17	2005-08-04	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
BRPI0714886B8 (pt)	2006-07-10	2021-05-25	Paion Uk Ltd	sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
WO2009088054A1 (ja)	2008-01-11	2009-07-16	Astellas Pharma Inc.	精巣の疼痛又は不快感行動及び頻尿併発モデル動物
EP2450039A1 (en)	2010-11-08	2012-05-09	PAION UK Ltd.	Dosing regimen for sedation with CNS 7056 (Remimazolam)
PE20150683A1 (es) *	2012-05-22	2015-06-03	Paion Uk Ltd	Composiciones que comprenden benzodiazepinas de accion corta
AR094963A1 (es)	2013-03-04	2015-09-09	Ono Pharmaceutical Co	Reacción de oxidación excelente en el índice de conversión

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2652352A1 (fr)	1989-09-28	1991-03-29	Jouveinal Sa	Benzodiazepines, leur procede et intermediaires de preparation et leurs applications en therapeutique.
FR2725719B1 (fr)	1994-10-14	1996-12-06	Jouveinal Inst Rech	Diazepino-indoles inhibiteurs de phosphodiesterases iv
FR2746800B1 (fr) *	1996-03-29	1998-06-05	Jouveinal Inst Rech	Diazepino-indoles inhibiteurs de phosphodiesterases 4
FR2762841B1 (fr)	1997-04-30	1999-07-02	Jouveinal Inst Rech	Diazepino-indolones inhibitrices de phosphodiesterases iv

2000
- 2000-06-09 EP EP00401646A patent/EP1161949A1/en not_active Withdrawn
2001
- 2001-05-11 CA CA002347337A patent/CA2347337A1/en not_active Abandoned
- 2001-06-05 CZ CZ20011999A patent/CZ20011999A3/cs unknown
- 2001-06-06 EA EA200100515A patent/EA200100515A3/ru unknown
- 2001-06-06 PL PL01347922A patent/PL347922A1/xx not_active Application Discontinuation
- 2001-06-06 ZA ZA200104616A patent/ZA200104616B/xx unknown
- 2001-06-07 AR ARP010102725A patent/AR030291A1/es not_active Application Discontinuation
- 2001-06-07 US US09/876,719 patent/US6544983B2/en not_active Expired - Fee Related
- 2001-06-07 IL IL14363601A patent/IL143636A0/xx unknown
- 2001-06-07 MX MXPA01005726A patent/MXPA01005726A/es unknown
- 2001-06-07 NZ NZ512222A patent/NZ512222A/xx unknown
- 2001-06-07 SK SK783-2001A patent/SK7832001A3/sk unknown
- 2001-06-07 AU AU51813/01A patent/AU5181301A/en not_active Abandoned
- 2001-06-07 BR BR0102289-0A patent/BR0102289A/pt not_active IP Right Cessation
- 2001-06-08 HU HU0102388A patent/HUP0102388A3/hu unknown
- 2001-06-08 CN CN01120850A patent/CN1345725A/zh active Pending
- 2001-06-08 JP JP2001174372A patent/JP2002138090A/ja active Pending
- 2001-06-08 KR KR1020010031887A patent/KR20010111457A/ko not_active Withdrawn
- 2001-06-08 NO NO20012831A patent/NO20012831L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HUP0102388A2 (hu)	2002-04-29
EP1161949A1 (en)	2001-12-12
IL143636A0 (en)	2002-04-21
KR20010111457A (ko)	2001-12-19
HUP0102388A3 (en)	2004-11-29
US6544983B2 (en)	2003-04-08
CZ20011999A3 (cs)	2002-04-17
EA200100515A2 (ru)	2001-12-24
AU5181301A (en)	2001-12-13
AR030291A1 (es)	2003-08-20
CN1345725A (zh)	2002-04-24
HU0102388D0 (en)	2001-08-28
ZA200104616B (en)	2002-10-30
PL347922A1 (en)	2001-12-17
NO20012831D0 (no)	2001-06-08
NO20012831L (no)	2001-12-10
CA2347337A1 (en)	2001-12-09
JP2002138090A (ja)	2002-05-14
NZ512222A (en)	2002-10-25
EA200100515A3 (ru)	2002-06-27
MXPA01005726A (es)	2003-08-20
US20020010175A1 (en)	2002-01-24
BR0102289A (pt)	2002-03-12

Publication	Publication Date	Title
US5945416A (en)	1999-08-31	Method for treating pain
JP2015028085A (ja)	2015-02-12	特定のジアリールヒダントインおよびジアリールチオヒダントイン化合物
EP3722291B1 (en)	2023-07-19	Indolinone compounds and their use in the treatment of fibrotic diseases
HRP20050205A2 (en)	2005-10-31	Benzensulfonate of 4-fluoro-2-cyanopyrrolidine derivative
SK7832001A3 (en)	2002-05-09	Diazepinoindoles for treating chronic obstruction bronchopulmonary disease
KR20040029323A (ko)	2004-04-06	Ｐｄｅ-4 저해제 및 ｈ1-수용체 길항제를 포함하는 조성물및 호흡기 질환 치료제 제조를 위한 이들의 용도
US6258807B1 (en)	2001-07-10	Method for treating pain
CN101232880A (zh)	2008-07-30	Hdac抑制剂在治疗骨髓瘤中的用途
IE80774B1 (en)	1999-02-10	Nmda antagonists
EP1161950A1 (en)	2001-12-12	Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
SK286040B6 (sk)	2008-01-07	Farmaceutická kompozícia obsahujúca 1-(2-naft-2-yletyl)-4-(3- trifluórmetylfenyl)-1,2,3,6-tetrahydropyridín hydrochlorid a donepezil alebo takrín
US20050070577A1 (en)	2005-03-31	Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
CN101926802A (zh)	2010-12-29	一种喹唑啉类化合物的用途
RS51707B (sr)	2011-10-31	Kombinacija leka sastavljena od r, r - formoterola i ciklezonida
HK1044884A1 (en)	2002-11-08	Treatment of chronic obstructive pulmonary disease with DIAZEPINOINDOLES
WO2006076318A1 (en)	2006-07-20	Monopotassium salt of an ikb kinase inhibitor
SK1292003A3 (en)	2003-08-05	Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
CN120899911A (zh)	2025-11-07	JAK抑制剂或Janus激酶蛋白降解剂治疗纤维化的用途和方法
WO2010074607A2 (ru)	2010-07-01	Действующее вещество и фармацевтическая композиция для лечения алкогольной зависимости, способ получения и применения
KR19990087716A (ko)	1999-12-27	과도한 공격성의 치료 방법
Kondo et al.	2012	The discovery of Samsca®(Tolvaptan): the first oral nonpeptide vasopressin receptor antagonist
WO1995027489A1 (en)	1995-10-19	Composition for treating neurological disorders
JPS5973515A (ja)	1984-04-25	肝障害抑制剤
KR19990087712A (ko)	1999-12-27	불면증의 치료 방법
MXPA98007438A (en)	1999-04-06	Medications to treat the insom